Patient Death Casts Cloud Over Roche Emicizumab Hemophilia Trial

The death of a patient during the HAVEN 1 study of Roche's investigational hemophilia product, emicizumab, may be nothing to panic about, but it is increasing concerns over its likely impact on the potential blockbuster drug's label.